Jonathan Mow
Vorstandsvorsitzender bei PHASEBIO PHARMACEUTICALS, INC.
Aktive Positionen von Jonathan Mow
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| PHASEBIO PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 01.09.2014 | - |
| Vorstandsvorsitzender | 01.09.2014 | - | |
| Corporate Officer/Principal | 04.12.2012 | 01.09.2014 | |
Veralox Therapeutics, Inc.
 Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | Vorstandsvorsitzender | 20.06.2023 | - |
Karriereverlauf von Jonathan Mow
Ehemalige bekannte Positionen von Jonathan Mow
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01.03.2007 | - |
Corus Pharma, Inc.
 Corus Pharma, Inc. Pharmaceuticals: MajorHealth Technology Corus Pharma, Inc. develops drugs to treat needs in infectious diseases and respiratory areas. The firm's core competencies reside in the identification of drugs, rapid clinical development, and FDA approval of its products. The firm was founded in January 2001 by A. Bruce Montgomery and is headquartered in Seattle, WA. | Gründer | 01.01.2001 | 01.01.2006 |
| Unternehmenssekretär | 01.01.2001 | 01.01.2006 | |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.1995 | 01.01.1997 |
| Syntex Laboratories, Inc. | Corporate Officer/Principal | - | - |
| Lederle International | Corporate Officer/Principal | - | - |
PathoGenesis Corp
 PathoGenesis Corp BiotechnologyHealth Technology Part of Novartis AG, PathoGenesis Corp is a private company that develops and markets innovative treatments for chronic infectious diseases. The company is based in Seattle, WA. The company was founded by Isaac Blech. PathoGenesis was acquired by Chiron Corp. on September 19, 2000 for $639.75 million. | Corporate Officer/Principal | - | - |
Ausbildung von Jonathan Mow
| University of California, Berkeley | Undergraduate Degree |
| Tepper School of Business | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 11 |
Operativ
| Corporate Officer/Principal | 6 |
| Chief Executive Officer | 2 |
| Founder | 1 |
Sektoral
| Health Technology | 7 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| PHASEBIO PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Corus Pharma, Inc.
Corus Pharma, Inc. Pharmaceuticals: MajorHealth Technology Corus Pharma, Inc. develops drugs to treat needs in infectious diseases and respiratory areas. The firm's core competencies reside in the identification of drugs, rapid clinical development, and FDA approval of its products. The firm was founded in January 2001 by A. Bruce Montgomery and is headquartered in Seattle, WA. | Health Technology |
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
PathoGenesis Corp
PathoGenesis Corp BiotechnologyHealth Technology Part of Novartis AG, PathoGenesis Corp is a private company that develops and markets innovative treatments for chronic infectious diseases. The company is based in Seattle, WA. The company was founded by Isaac Blech. PathoGenesis was acquired by Chiron Corp. on September 19, 2000 for $639.75 million. | Health Technology |
| Lederle International | |
| Syntex Laboratories, Inc. | |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | Health Technology |
- Börse
- Insiders
- Jonathan Mow
- Erfahrung
